Home/Filings/4/0001193805-24-000324
4//SEC Filing

Nash Duane 4

Accession 0001193805-24-000324

CIK 0001280776other

Filed

Mar 5, 7:00 PM ET

Accepted

Mar 6, 9:52 PM ET

Size

25.2 KB

Accession

0001193805-24-000324

Insider Transaction Report

Form 4
Period: 2024-03-04
Nash Duane
See Remarks
Transactions
  • Disposition to Issuer

    Stock Option

    2024-03-04120,0000 total
    Exercise: $17.00Exp: 2030-10-22Common Stock (120,000 underlying)
  • Disposition to Issuer

    Stock Option

    2024-03-0490,0000 total
    Exercise: $15.44Exp: 2031-04-15Common Stock (90,000 underlying)
  • Disposition to Issuer

    Stock Option

    2024-03-0475,0000 total
    Exercise: $10.88Exp: 2032-03-10Common Stock (75,000 underlying)
  • Award

    Stock Option

    2024-03-04+379,959379,959 total
    Exercise: $1.72Common Stock (379,959 underlying)
  • Disposition to Issuer

    Stock Option

    2024-03-0419,9730 total
    Exercise: $13.63Exp: 2029-07-22Common Stock (19,973 underlying)
  • Disposition to Issuer

    Stock Option

    2024-03-0430,0000 total
    Exercise: $12.30Exp: 2030-07-02Common Stock (30,000 underlying)
  • Disposition to Issuer

    Stock Option

    2024-03-0410,0000 total
    Exercise: $3.40Exp: 2032-06-15Common Stock (10,000 underlying)
  • Disposition to Issuer

    Stock Option

    2024-03-049,9860 total
    Exercise: $13.63Exp: 2029-07-22Common Stock (9,986 underlying)
  • Disposition to Issuer

    Stock Option

    2024-03-0415,0000 total
    Exercise: $12.30Exp: 2030-07-02Common Stock (15,000 underlying)
  • Disposition to Issuer

    Stock Option

    2024-03-0410,0000 total
    Exercise: $14.77Exp: 2031-06-10Common Stock (10,000 underlying)
Footnotes (1)
  • [F1]On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date.

Issuer

IMMUNIC, INC.

CIK 0001280776

Entity typeother

Related Parties

1
  • filerCIK 0001591098

Filing Metadata

Form type
4
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 9:52 PM ET
Size
25.2 KB